Plasma anticoagulant having virus inactivation function

Abstract

The invention relates to a plasmid anticoagulant having a virus inactivation function. With 4% sodium citrate which is collected in a blood test as a basic anticoagulant, the virus inactivation function of the plasmid anticoagulant is achieved by adding one or more virus inactivating agents selected from sodium caprylate, formaldehyde and [beta]-propiolactone. With the application of the plasma anticoagulant having a recheck function provided by the invention, the risk of personnel infection due to exposure of positive plasma in a storing, transporting or using process after the collection of the plasma can be effectively prevented, so that the bio-safety of the plasma in an entire life cycle from the collection of the plasma can be guaranteed.

Description

technical field [0001] This patent provides a double-check anticoagulant used in the process of collecting human plasma for blood product production, which has multiple functions of protease inactivation and virus inactivator plasma anticoagulation. It effectively ensures that the degradation of protein components in the process of storage, transportation and use after plasma collection is minimal, and greatly improves its biosafety function, avoiding the risk of infection caused by positive plasma exposure. Ensure the biosafety of plasma throughout its life cycle from the time of plasma collection. Background technique [0002] 1 Viral inactivator for human vaccine products. [0003] There are two main types of vaccine inactivators: formaldehyde and beta-propiolactone (BPL). Most domestic vaccines use formaldehyde to inactivate, while foreign countries mostly use beta-propiolactone. [0004] Formaldehyde and its 37-40% solution are formalin. Formaldehyde has a destructi...

AI Technical Summary

Problems solved by technology

[0011] 3. The biosafety dilemma of plasma collection

In the current plasma collection, if there is virus-positive plasma, it needs to be confirmed by two inspections and compliance inspections between the station and the plasma-using enterprise with an interval of 3 months. After the positive plasma is confirmed, it will be concentrated under the supervision of the regulatory department. destroy

It can be seen from this that, as positive plasma, three months after the collection of the disaster, it will be destroyed after going through several storage links and transportation methods, but any exposure during this process cannot be effectively processed. Even the exposed personnel in this process are unaware

This brings great potential safety hazards to plasma management and users